<?xml version="1.0" encoding="UTF-8"?>
<p>This study was approved by an Institutional Review Board at Fred Hutchinson Cancer Research Center (Fred Hutch) in accordance with the Declaration of Helsinki and the FDA, and conformed to the National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules. Informed consent was obtained from all patients or guardians. FA patients aged 4 years or over were diagnosed by a positive test for increased sensitivity to chromosomal breakage with mitomycin C (MMC) or diepoxybutane. Correction of melphalan hypersensitivity following retroviral transduction of the FANCA cDNA identified Patient 3 as belonging to the FA-A complementation group. (
 <italic>Online Supplementary Table S1</italic>). FA-A patients who demonstrated normal karyotype in BM analyses as defined in the trial were considered eligible for the study. Characteristics of enrolled patients are available in 
 <xref rid="t1-1031806" ref-type="table">Table 1</xref>.
</p>
